AVAD: Asthma With Small Airways Dysfunction

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to describe asthma phenotype with small airways dysfunction, in a multiparametric manner, with clinical, biological, morphological and genetic elements compared with asthma with proximal airways obstruction. The objective of this study is also to complete the clinical, immunobiological and morphological analysis of asthma with small airways dysfunction.

Official Title
-----------------
AVAD: Asthma With Small Airways Dysfunction. Clinical, Immunobiological, Tomodensitometric Description, Genetic Signature Compared With Asthmatic Population With Proximal Airways Obstruction

Conditions
-----------------
ASTHMA

Intervention / Treatment
-----------------
* Genetic: asthma with proximal airways obstruction phenotype profile description with clinical, biological, morphologic and genetic elements.
* Genetic: asthma with small airways dysfunction phenotype profile description with clinical, biological, morphologic and genetic elements.


Participation Criteria
=================
Eligibility Criteria
-----------------
General Inclusion Criteria: man or woman age ≥ 18 years asthma inform consent signed affiliated to health insurance Specific inclusion criteria : asthma with proximal airways obstruction GROUP Maximal Voluntary Ventilation (MMV)<80% MMV / Forced Vital Capacity (FVC)≤70% Carbon Monoxide Transfer Coefficient (KcO)>80% Specific inclusion criteria : asthma with small airways dysfunction GROUP Maximal Voluntary Ventilation (MMV)≥80% MMV / Vital Capacity(VC)>70% Carbon Monoxide Transfer Coefficient (KcO)>80% General Exclusion Criteria: pregnant woman or breastfeeding patient participating to other biomedical research patient who have participated to other biomedical research within the past 3 months patient refusing to sign the inform consent Specific exclusion criteria : Patient who stopped smoking since less than 12 months Pathological state related to obstructive distal airway damage Broncho-pulmonary infectious disease within the past 4 weeks Solid tumor curated by chemotherapy or chest radiotherapy Chronic respiratory disease Asthma exacerbation within the past 3 months Oral or systemic corticotherapy within the past 3 months

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: asthma with proximal or diffuse lung damage<br> | Genetic: asthma with proximal airways obstruction phenotype profile description with clinical, biological, morphologic and genetic elements.<br>* symptoms, medical history, date of start, date of aggravation, comorbidities, increased factors related to asthma, blood eosinophils, blood periostin, allergologic patch test, igE analysis, tomodensitometric test.<br>|
| Experimental: asthma with small airway prevailing damage<br> | Genetic: asthma with small airways dysfunction phenotype profile description with clinical, biological, morphologic and genetic elements.<br>* symptoms, medical history, date of start, date of aggravation, comorbidities, increased factors related to asthma, blood eosinophils, blood periostin, allergologic patch test, IgE analysis, tomodensitometric test.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| mRNA expression levels. | mRNA expression levels will be measured by microarray analysis. | maximum 4 weeks after the inclusion visit. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| clinical asthma profile : symptoms | symptoms | maximum 4 weeks after the inclusion visit. | 
| clinical asthma profile : medical history | medical history | maximum 4 weeks after the inclusion visit. | 
| clinical asthma profile : date of start | date of start | maximum 4 weeks after the inclusion visit. | 
| clinical asthma profile : date of aggravation | date of aggravation | maximum 4 weeks after the inclusion visit. | 
| clinical asthma profile : comorbidities | comorbidities | maximum 4 weeks after the inclusion visit. | 
| clinical asthma profile : increased factors related to asthma. | increased factors related to asthma. | maximum 4 weeks after the inclusion visit. | 
| biological asthma profile :blood eosinophils | blood eosinophils | maximum 4 weeks after the inclusion visit. | 
| biological asthma profile : blood periostin | blood periostin | maximum 4 weeks after the inclusion visit. | 
| biological asthma profile : allergologic patch test | allergologic patch test | maximum 4 weeks after the inclusion visit. | 
| biological asthma profile : IgE analysis | IgE analysis | maximum 4 weeks after the inclusion visit. | 
| morphological asthma profile : Chest X Ray (tomodensitometric test). | Chest X Ray (tomodensitometric test). | maximum 4 weeks after the inclusion visit. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Asthma, phenotype, small, airway, proximal, dysfunction